IMO-3100 is a dual antagonist of Toll-like receptor (TLR) 7 and TLR9, which is indicated as a therapy for autoimmune and inflammatory diseases.
In July 2011, the company submitted a Phase 2 protocol to evaluate IMO-3100 in patients with psoriasis over a 12-week treatment period, which was put on clinical hold by the FDA.
In October 2011, the company submitted a new Phase 2 protocol to evaluate IMO-3100 in patients with psoriasis over a 4-week treatment period, which led to notification of FDA authorization to proceed.
Idera chairman and CEO Sudhir Agrawal said the company is geared up to conduct Phase 2 trial of dual-TLR antagonist to treat autoimmune diseases and are likely to initiate the study in the first half of 2012.